Waterhouse DJ, Fitzpatrick CRM, Pogue BW, O’Connor JPB, Bohndiek SE. Translation of Optical Imaging Biomarkers: Opportunities and Challenges. Nat Biomed Eng 3: 339-353 

O’Connor JPB, Robinson SP, Waterton JC. Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI. Br J Radiol 92: 20180642 doi: 10.1259/bjr.20180642


Datta, M.C. Aznar, M. Dubec, G.J. Parker, J. O’Connor. Delivering functional imaging on the MR-Linac: current challenges and potential solutions. Clin Oncol, 30(11), 702-710 doi: 10.1016/j.clon.2018.08.005

Salem A, Asselin M-C, Reymen B, Jackson A, Lambin P, West CML, O’Connor JPB, Faivre-Finn C. Targeting hypoxia to improve non-small cell lung cancer outcome. J Nat Can Inst 110: 14-30 doi: 10.1093/jnci/djx160


O’Connor JPB. Rethinking the role of clinical imaging. eLife 6: e30563 doi: 10.7554/eLife.30563

O’Connor JPB. Cancer heterogeneity and Imaging. Semin Cell Dev Biol 64: 48-57. doi: 10.1016/j.semcdb.2016.10.001


O’Connor JPB, Rose CJ, Waterton JC, Carano RAD, Parker GJM, Jackson A. Imaging intratumor heterogeneity: role in therapy response, resistance and clinical outcome. Clin Cancer Res 21: 249-257. doi: 10.1158/1078-0432.CCR-14-0990


O’Connor JPB, Jayson GC. Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors? Clin Cancer Res 18: 6588-6598 doi: 10.1158/1078-0432.CCR-12-1501

O’Connor JPB, Jackson A, Parker GJ, Roberts C, Jayson GC. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol 9: 167-177. doi: 10.1038/nrclinonc.2012.2

Asselin M-C, O’Connor JPB, Boellard R, Thacker NA, Jackson A. Quantifying heterogeneity in human tumours using MRI and PET. Eur J Cancer 48: 447-455. doi: 10.1016/j.ejca.2011.12.025


O’Connor JPB, Jackson A, Asselin M-C, Buckley DL, Parker GJM, Jayson GC. Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. Lancet Oncol 9: 756-766. doi: 10.1016/S1470-2045(08)70196-7


O’Connor JPB, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96: 189-95. doi: 10.1038/sj.bjc.6603515

Jackson A, O’Connor JP, Parker GJ, Jayson GC. Imaging tumor vascular heterogeneity and angiogenesis using DCE-MRI. Clin Cancer Res 13: 3449-3459 doi: 10.1158/1078-0432.CCR-07-0238